In Europe, use of intravenous tissue plasminogen activator (tPA) in patients older than 80 years is discouraged because these patients have been excluded from certain past clinical trials. A new retrospective, observational study shows that tPA can substantially improve functional outcome after ischaemic stroke in patients aged 80–89 years.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Reuter, B. et al. Intravenous thrombolysis for acute ischaemic stroke in the elderly: data from the Baden-Wuerttemberg Stroke Registry. Eur. J. Neurol. http://dx.doi.org/10.1111/ene.12829 (2015).
Boulouis, G. et al. Intravenous thrombolysis for acute cerebral ischaemia in old stroke patients ≥80 years of age. J. Neurol. 259, 1461–1467 (2012).
Bhatnagar, P. et al. Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age. J. Neurol. Neurosurg. Psychiatry 82, 712–717 (2011).
IST-3 collaborative group et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet 2012, 2352–2635 (2012).
Arauz, A., Berge, E. & Sandercock, P. Third International Stroke Trial 3: an update. Curr. Opin. Neurol. 27, 8–12 (2014).
Yayan, J. Effectiveness of alteplase in the very elderly after acute ischemic stroke. Clin. Interv. Aging 8, 963–974 (2013).
Longstreth, W. T. Jr, Katz, R., Tirschwell, D. L., Cushman, M. & Psaty, B. M. Intravenous tissue plasminogen activator and stroke in the elderly. Am. J. Emerg. Med. 28, 359–363 (2010).
Mateen, F. J. et al. Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older. Mayo Clin. Proc. 84, 334–338 (2009).
Acknowledgements
S.R.L. has received grants U10NS077378 and U10NS080377 from the NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.R.L. serves on the scientific advisory and steering committee of and as a site investigator for PRISMS, a Genentech-sponsored, phase IIIb, randomized, placebo-controlled clinical trial of intravenous tissue plasminogen activator (IV tPA) for minor stroke. He has also received an investigator-initiated grant from Genentech to study physician decision making in the use of tPA for minor and rapidly improving stroke. He has provided expert testimony for both patients and physicians concerning IV tPA. S.W.L. declares no competing interests.
Rights and permissions
About this article
Cite this article
Law, S., Levine, S. Support for IV tPA in ischaemic stroke in elderly people. Nat Rev Neurol 12, 8–9 (2016). https://doi.org/10.1038/nrneurol.2015.231
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.231